Targeting aging senescent cells to combat aging with senotherapy is currently undergoing research in clinical trials. One such study researched the use of Carlson fish oil to improve immune senescence biomarkers CD28, CD57, on the surface of CD4+ and CD8+ T lymphocytes in aging participants 40-70 years old with HIV infection. The intervention groups received 1.6 grams of omega-3 fatty acids daily for 12 weeks. Published results were less than encouraging however with no significant difference in immune senescence measurements in participants. Another phase I/II clinical trial NCT04063124 researching targeting aging senescent cells was recently completed by the University of Texas Health Science Center at San Antonio. Five early-stage AD patients were enrolled and received 100 mg of dasatinib and 1000 mg of quercetin every two weeks for twelve weeks. The outcome measurements of brain penetration for both compounds and AD and senescence biomarkers were collected. Interpretative results have yet to be published but the results of this pilot study will guide researchers in developing a larger phase II trial researching senolytic agents for the modulation of Alzheimer's disease progression. 671 Lastly, we examine phase II clinical trial NCT04733534 currently recruiting 60 participants. St. Jude Children's Research Hospital will evaluate two senolytic regimens for their cellular senescence biomarker reduction and frailty improvement in adult survivors of childhood cancer. Treatment groups will receive either oral Dasatinib (100 mg/day) and Quercetin (500 mg twice daily) on days 1, 2, 3, 30, 31, 32 or oral Fisetin (20mg/kg/day) on days 1, 2, 30 and 31. Outcome measurement of walking speed and blood senescent cells (p16INK4A) levels will be recorded. If this pilot study is successful, it too will provide evidence needed for a continued phase II trial to determine further efficacy. 672 The testosterone trials have shown that increasing testosterone levels in older men with low testosterone has documented benefits. This trial paves the way for larger trials to explore the risks and efficacy deeper and has helped influence physician decisions regarding testosterone treatment in older men.